PTEN and prostate cancer: Setting the cutoffs as 30% for homozygous and 20% for heterozygous deletion, Yoshimoto et al. identified the presence of heterozygous and homozygous PTEN deletion in 39% and 5% prostate cancer patients, respectively [8].